

A Novel Blood Test to Diagnose Disease and its Origins through Identification of Cell Free DNA (Yissum)
code: 6-2017-4530

[Nir Friedman](#), HUJI, Faculty of Science, The Alexander Silberman Institute for Life Sciences
Ronen SADEH, HUJI, Faculty of Science

Keywords	cell free DNA diagnosis, liquid biopsies, methylation patterns, histone modification
Current development stage	TRL3 - hypothesis testing and initial POC demonstrated in limited # of in-vitro models

Application

The existing sequence methods don't enable personal cheap screening in blood for developing diseases.

Multiplexing diagnosis of epigenetics and mutations is separated from other liquid biopsies.

Currently, there is no technology for broad detection of any pathological condition at unbiased, low cost manner that can be joined with other diagnosis

Our Innovation

A novel approach interrogates epigenetic modification in cfDNA.

- **Unbiased detection of any pathological stage without a priori looking to diseases (good for screening).**
- **Gives multiple information on many physiological parameters of the subject.**
- **A very small sample of plasma is required.**
- **Sample not chemically damaged. It can be used for further diagnosis tests and be combined with existing diagnosis.**

Opportunity

- **Detects broad pathological sites such as multiple sclerosis, cancer and Type 2 Diabetes at low cost.**
- **A novel new approach for liquid biopsy diagnosis in cancer and other diseases.**
- **Personalized Medicine treatment monitoring.**

Contact for more information:

Shani Bullock , VP, Business Development, Healthcare, +972-2-6586608

Yissum Research Development Company of the Hebrew University of Jerusalem
Hi-Tech Park, Edmond J. Safra Campus, Givat-Ram, Jerusalem P.O. Box 39135, Jerusalem 91390
Israel Telephone: 972-2-658-6688, Fax: 972-2-658-6689